Prognostic Value of Maximal and Submaximal Exercise Performance in Fontan Patients < 15 Years of Age

Am J Cardiol. 2021 Sep 1:154:92-98. doi: 10.1016/j.amjcard.2021.05.049. Epub 2021 Jul 4.

Abstract

In patients after Fontan completion exercise capacity is significantly reduced. Although peak oxygen consumption (VO2peak) is a strong prognostic factor in many cardiovascular diseases, it requires the achievement of a maximal effort. Therefore, submaximal exercise parameters such as oxygen uptake efficiency slope (OUES) may be of value. In the present observational study we evaluated the exercise capacity with maximal and submaximal parameters in a group of Fontan patients with an extracardiac conduit and determined their prognostic value. Sixty Fontan patients followed up in the Leiden University Medical Center who have performed an exercise test were included in this retrospective study. Exercise tests were performed at a median age of 11 years. Fontan patients showed on average lower values for all exercise parameters compared to reference values from a healthy dataset as shown by the %predicted values: VO2peak%:mean 66%(95%CI:64 to 74) and OUES%:mean 72%(95%CI:67 to 77). Twenty percent of the patients were not able to achieve an RER>1.0. RER showed a moderate positive correlation with VO2peak but not with OUES. There was a deterioration of VO2peak% and OUES% over time. OUES was significantly lower in patients with cardiac events in the follow up period. Fontan patients have an impaired exercise performance even at young ages and it deteriorates with age. An important percentage of Fontan patients is not able to reach maximal effort so the use of submaximal parameters, like OUES, should be considered as part of the evaluation. Moreover, OUES could have a prognostic value in this group of patients.

MeSH terms

  • Adolescent
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Anticoagulants / therapeutic use
  • Child
  • Exercise Test
  • Exercise Tolerance*
  • Female
  • Fontan Procedure*
  • Heart Defects, Congenital / physiopathology*
  • Heart Defects, Congenital / therapy
  • Humans
  • Male
  • Oxygen Consumption / physiology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Anticoagulants
  • Platelet Aggregation Inhibitors